or smoked marijuana in the treatment of war related PTSD in veterans, which will evaluate efficacy and safety of multiple strains of herbal cannabis. The study has received FDA approval. MAPS is pursuing the purchase of appropriate strains from the US federal government. Sponsored efforts by Prof. Lyle Craker, Medicinal Plant Program, UMass Amherst Department of Plant and Soil Sciences, to obtain a license from the Drug Enforcement Administration for a marijuana production facility. Sponsored analytical research into the effects of the marijuana vaporizer, leading to the first human study of marijuana vaporizers conducted by Dr. Donald Abrams of the University of California, San Francisco. Funded the successful efforts of Dr. Donald Abrams to obtain approval for the first human study in 15 years into the therapeutic use of marijuana, along with a $1 million grant from the National Institute on Drug Abuse. Obtained Orphan Drug designation from the FDA for smoked marijuana in the treatment of AIDS Wasting Syndrome. Supported long-term follow-up studies of pioneering research with LSD and psilocybin originally conducted in the 1950s and 1960s. Sponsoring research by Dr. Evgeny Krupitsky into ketamine-assisted psychotherapy as a potential treatment for heroin addiction and alcoholism. Sponsoring programs and services at festivals, community events, churches, and schools that provide psychedelic harm reduction and education. A clinical study evaluating the treatment of cluster headaches using low doses of the tryptamine psilocybin (found in psilocybin mushrooms) is being developed by researchers at Harvard Medical School, McLean Hospital in conjunction with MAPS. Performed several small clinical studies described below, and in some cases, published the results in scientific journals. Organization Board and staff MAPS is governed by a board of directors including John Gilmore, David Bronner, Robert J. Barnhart, and Rick Doblin. Ashawna Hailey served on the board until her death in 2011. Funding MAPS is a nonprofit 501(c)(3) research and educational organization, funded by donations from individuals and foundations. Donations to MAPS can be restricted to fund a specific project, or be unrestricted. MAPS also receives revenue from conferences and events, such as the Psychedelic Science conference, as well as from the sale of books, merchandise, and art. With a policy of transparency in financial matters, MAPS publishes a detailed annual financial report. On August 20, 2020, having raised $30 million in non-profit donations in less than six months, MAPS and the Psychedelic Science Funders Collaborative (PSFC) announced the completion of the